What is it? Why is it important?

Administrative tasks include to:

  • Notify the completion, discontinuation, or interruption of the study protocol to the Ethics Committee (EC) and if applicable regulatory Authorities (RA) (i.e. Swissmedic for risk-category B and C, international)
  • Update study registries to inform the public and the scientific community of the completion, discontinuation, or interruption of the study protocol
  • Archive the study for a predetermined period of time (i.e. this can encompass several years). This requires that the protocol including potential protocol amendments are archived in such a way as to remain traceable and legible during the entire archiving period
  • Document lessons learned. The implementation of a study protocol always includes many challenges. How these challenges are handled during study conduct are important lessons learned. Thus, valuable know can be transferred and mistakes can be prevented when planning future studies and writing future protocols

What do I need to do?

As a SP-INV:

  • Notify the EC/RA regarding the completion, discontinuation, or interruption of your study
  • Update study registries applied during the study set-up and conduct phase
  • Make yourself familiar with required archiving requirements, and:
    • Write an archiving SOP that defines archiving standards (e.g. access to protected archiving premises, how to ensure documents are protected against theft and destruction such as fire, humidity, and rodents)
    • Ensure the protocol including other archived documents remain legible during the entre archiving period
  • Document lessons learned and ensure they remain accessible to be consulted when planning future studies

Where can I get help?

Your local CTU can support you with experienced staff regarding this topic

External Links

Swissethics

Swissmedic website – see in particular

  • Template: End of study notification

Swiss Law

ClinO –  see in particular article

  • Art. 38 Notification upon study completion, discontinuation or interruption

ClinO-MD – see in particular articles

  • Art. 36 Reporting the end, early termination and interruption of a clinical trial
  • Art. 38 Notification and reporting to Swissmedic

HRO – see in particular articles

  • Art. 22 Notification upon completion or discontinuation of a research project
  • Art. 22, 36, 40, 43 Notification of completion or discontinuation of research projects involving biological material and health-related data
Abbreviations
  • CTU – Clinical Trials Unit
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • EC/RA  – Ethics Committee / Regulatory Authorities
  • HRO – Human Research Ordinance
  • RA – Regulatory Authorities
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor Investigator
Completion ↦ Protocol ↦ Administrative Tasks ↦ Procedures
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Basic Drug or Device
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Statistics
Completion Drug or Device
Current Path (click to copy): Completion ↦ Protocol ↦ Administrative Tasks ↦ Procedures

Please note: the Easy-GCS tool is currently under construction.